Connect with us

Business

EMA Gives Positive Opinion Regarding Tetra Bio-Pharma Inc.’s (OTCMKTS: TBPMF)QIXFEEL Drug In CRPS Treatment

Published

on

Tetra Bio-Pharma Inc. (OTCMKTS: TBPMF) has received a positive opinion from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) regarding its Orphan Drug Designation application for the experimental drug QIXLEEF as a possible Complex Regional pain Syndrome (CRPS) treatment. CRPS is a chronic neuropathic pain condition.

COMP issues positive opinion ion QIXLEEF

The company’s CEO and Chief Regulatory Officer, Guy Chamberland, said, “The positive opinion issued by the COMP is excellent news as Tetra continues to execute its regulatory strategy in Europe. An ODD brings several unique advantages, from a cost reduction in drug development, to an accelerated review process and market exclusivity for 10 years. Such strategy is cost and time effective and allows the company to easily gain market shares in a competitive free environment. If granted, this would represent QIXLEEF’s second ODD as a potential treatment for CRPS, in addition to the ODD granted by the U.S. FDA in March 2018. We firmly believe that QIXLEEF will be a safe and effective medicine for pain management and an alternative to opioids.”

QIXLEEF has the potential of being a CRPS treatment 

The COMP’s favorable conclusion will be forwarded to the European Commission, which is likely to grant orphan status within 30 days. The regulatory body found that QIXLEEF met the requirements for orphan medicinal product designation and recommended that it be granted based on a majority of 30 votes out of 31 cast.

Also, the EMA COMP established that QIXLEEF is eligible as an orphan drug for treatment CRPS because the medicinal product is intended to treat a chronic debilitating condition. Equally, this rare condition’s estimated prevalence in the EU is 4.4 in 10,000 people, with available data from published literature showing peripheral neuropathic pain improvement in individuals treated with cannabinoid-based medications.

Since QIXLEEF targets an orphan condition, clinical studies will be carried with a considerably smaller patient number, and it qualifies for conditional approval in EU member states.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

FEATURED STORIES

Business19 hours ago

Affinor Growers Inc. (OTCMKTS: RSSFF) Closes Non-Brokered Placement of 10.43 Million Units And Appoints Patrick Carey To Board

Post Views: 4 Affinor Growers Inc. (OTCMKTS: RSSFF) has announced the closing of a non-brokered placement of 10.43 million units...

Business19 hours ago

CEA Industries Inc. (OTCMKTS: SRNA) Announce $2.1 million contract with a Maryland facility

Post Views: 36 CEA Industries Inc. (OTCMKTS: SRNA), which does business as Surna Cultivation Technologies, has announced that it received...

Business19 hours ago

Decibel Cannabis Company Inc. (OTCMKTS: DBCCF) Expanding Recreational Cannabis Market Share And Announced Debt Refinancing

Post Views: 43 Decibel Cannabis Company Inc. (OTCMKTS: DBCCF) has offered an update about its latest Canadian recreational market share. ...

Business20 hours ago

Auxly Cannabis Group Inc. (OTCMKTS: CBWTF) Expanding Leadership In Cannabis 2.0- Sales With Increase In Market Share To 15%

Post Views: 56 Auxly Cannabis Group Inc. (OTCMKTS: CBWTF) has reported ongoing nationwide leadership in Cannabis 2.0 sales in 2021...

Business2 days ago

Ayr Wellness (OTCMKTS: AYRWF) Opens New Cannabis Dispensary in Pinellas, Florida, its 44th Location In The State

Post Views: 5 Ayr Wellness (OTCMKTS: AYRWF) has announced the opening of its latest dispensary in Pinellas, Florida. The Pinellas...

Business2 days ago

CLS Holding USA Inc. (OTCMKTS: CLSH) Announces 10% Revenue Growth in Q2 2022 As It Tops Concentrate Sales In Nevada

Post Views: 72 CLS Holding USA Inc. (OTCMKTS: CLSH), which operates as Cannabis Life Sciences, has announced its financial and...